Abstract:In situ glyco-editing on the cell surface can endow cellular glycoforms with new structures and properties; however, the lack of cell specificity and dependence on cells' endogenous functions plague the revelation of cellular glycan recognition properties and hamper the application of glyco-editing in complicated authentic biosystems. Herein, we develop a thermally triggered, cell-specific glyco-editing method for regulation of lectin recognition on target live cells in both single- and cocultured settings. The method relies on the aptamer-mediated anchoring of microgel-encapsulated neuraminidase on target cells and subsequent thermally triggered enzyme release for localized sialic acid (Sia) trimming. This temperature-based enzyme accessibility modulation strategy exempts genetic or metabolic engineering operations and, thus for the first time, enables tumor-specific desialylation on complicated tissue slices. The proposed method also provides an unprecedented opportunity to potentiate the innate immune response of natural killer cells toward target tumor cells through thermally triggered cell-specific desialylation, which paves the way for in vivo glycoimmune-checkpoint-targeted cancer therapeutic intervention.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c15212?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c15212</a>.Experimental section; scheme for preparation of thermally sensitive MG; evaluation of the influence from MG on detection of Neu concentration and Neu activity; effect of temperature on the Neu activity; study of the effects of various components or probes on cell viability; exclusion of the effects of F127, F127-LA, F127-LA-DA, and MG on Neu activity; demonstration of Apt binding specificity of @Apt toward MDA-MB-231 cells; optimization of experimental conditions for @Apt-based Sia trimming; analysis of the average amount of Neu released from cell-bound @Apt per cell; flow cytometric verification of cell-specific glyco-editing in cocultured cell setting; tumor-specific glyco-editing on tissue slices from subcutaneous MDA-MB-231 xenografts and normal breast tissues; demonstration of cell specificity of @Apt-based Sia trimming using bladder tumor tissue slices; demonstration of the successful isolation of NK cells from PBMCs; cell viability of separately cultured MDA-MB-231 and MCF-7 cells after incubation with NK cells; and flow cytometric verification of cell-specific potentiation of NK cell killing activity in cocultured cell setting (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c15212/suppl_file/am0c15212_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Specifically Editing Cancer Sialoglycans for Enhanced Immunotherapy In Vivo through Aptamer‐Enzyme Chimeras

Chemical Remodeling Cell Surface Glycans for Immunotargeting of Tumor Cells

Abstract IA010: Engineering human sialidase as novel cancer therapeutics by targeting sialoglycans

Targeted glycan degradation potentiates the anticancer immune response in vivo

Aptamer-Assisted Blockade of the Immune Suppressor Sialic Acid-Binding Immunoglobulin-Like Lectin-15 for Cancer Immunotherapy

Thermally Triggered, Cell-Specific Enzymatic Glyco-Editing: In Situ Regulation of Lectin Recognition and Immune Response on Target Cells

Sialic Acids Blockade‐Based Chemo‐Immunotherapy Featuring Cancer Cell Chemosensitivity and Antitumor Immune Response Synergies

Thermally Triggered, Cell-Specific Enzymatic Glyco-Editing: <i>In Situ</i> Regulation of Lectin Recognition and Immune Response on Target Cells

Targeted glycan degradation potentiates cellular immunotherapy for solid tumors

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9

Enzymatic interlocking aptamer-micelles for enhanced cellular internalization and nucleus-targeted cancer phototherapy

Sialidase-Chimeric Bioengineered Bacteria for Tumor-Sialoglycan-Triggered Solid Tumor Therapy

Safe Engineering of Cancer-Associated Fibroblasts Enhances Checkpoint Blockade Immunotherapy.

Genetically Edited Cascade Nanozymes for Cancer Immunotherapy

Leucine zipper-based SAIM imaging identifies therapeutic agents to disrupt the cancer cell glycocalyx for enhanced immunotherapy

Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells

Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy

Ultra‐Galactocation to Sialic Acid on Tumor Cells with A Penta‐Functional Dendritic Probe for Enhanced Immuno‐Killing

A Multiple Targeting Genome Editing System for Remodulation of Circulating Malignant Cells to Eliminate Cancer Immunosuppression and Restore Immune Responses

Ultra‐Galactocation to Sialic Acid on Tumor Cells with A Penta‐Functional Dendritic Probe for Enhanced Immune‐Killing